---
figid: PMC5173082__oncotarget-07-41612-g004
figlink: /pmc/articles/PMC5173082/figure/F4/
number: F4
caption: Gold symbols indicate phosphoproteins whose weighted scores were input into
  Ingenuity Pathway Analysis to generate the most likely downstream interactions.
  Inhibition of MTORC1 activity via temsirolimus or everolimus interaction with the
  p70S6k subunit releases the brake on MTORC2. Subsequent signaling through pAkt and
  pERK is predicted to stimulate molecules associated with hypoxia (HIF1α, EZH2) and
  insulin growth receptors (IGFR, IGF1), via interaction through STAT3. Possible expression
  of transcription factor POUF6, as well as potential interactions with micro RNA
  (miR)101 and the micro RNA precursor mir-26 is associated with increased EZH2 expression.
  Green lines indicate binding or phosphorylation that leads to activation of the
  downstream protein and red lines indicate phospho-inhibition. Targets of proposed
  therapies using metformin (pink) and vorinostat (blue) are indicated by dashed or
  dotted lines. The dotted lines indicate activation, and dashed lines indicate inhibition.
pmcid: PMC5173082
papertitle: 'Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway
  as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic
  pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis
  and therapeutic options.'
reftext: Robert E. Brown, et al. Oncotarget. 2016 Jul 5;7(27):41612-41621.
pmc_ranked_result_index: '142769'
pathway_score: 0.8347526
filename: oncotarget-07-41612-g004.jpg
figtitle: mTORC2/Akt pathway
year: '2016'
organisms:
- Homo sapiens
ndex: 9570ac67-df23-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5173082__oncotarget-07-41612-g004.html
  '@type': Dataset
  description: Gold symbols indicate phosphoproteins whose weighted scores were input
    into Ingenuity Pathway Analysis to generate the most likely downstream interactions.
    Inhibition of MTORC1 activity via temsirolimus or everolimus interaction with
    the p70S6k subunit releases the brake on MTORC2. Subsequent signaling through
    pAkt and pERK is predicted to stimulate molecules associated with hypoxia (HIF1α,
    EZH2) and insulin growth receptors (IGFR, IGF1), via interaction through STAT3.
    Possible expression of transcription factor POUF6, as well as potential interactions
    with micro RNA (miR)101 and the micro RNA precursor mir-26 is associated with
    increased EZH2 expression. Green lines indicate binding or phosphorylation that
    leads to activation of the downstream protein and red lines indicate phospho-inhibition.
    Targets of proposed therapies using metformin (pink) and vorinostat (blue) are
    indicated by dashed or dotted lines. The dotted lines indicate activation, and
    dashed lines indicate inhibition.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RICTOR
  - IRS1
  - HIF1A
  - IGF1R
  - STAT3
  - RPTOR
  - MTOR
  - MLST8
  - MAPKAP1
  - RPS6KB2
  - AKT3
  - AKT2
  - POU6F1
  - RPS6KB1
  - EZH2
  - MAPK3
  - AKT1
  - MAPK1
  - temsirolimus
  - metformin
genes:
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: IRS1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: HIF1A
  symbol: HIF1A
  source: hgnc_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: IGF1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: p70S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB2
  entrez: '6199'
- word: p-AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: p-AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: POU6F1
  symbol: POU6F1
  source: hgnc_symbol
  hgnc_symbol: POU6F1
  entrez: '5463'
- word: p70S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: EZH2
  symbol: EZH2
  source: hgnc_symbol
  hgnc_symbol: EZH2
  entrez: '2146'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: p-AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
chemicals:
- word: temsirolimus
  source: MESH
  identifier: C401859
- word: metformin
  source: MESH
  identifier: D008687
diseases: []
figid_alias: PMC5173082__F4
redirect_from: /figures/PMC5173082__F4
figtype: Figure
---
